STOCK TITAN

Kimball Electronics (KE) 10-K Filings

KE NASDAQ

Here are the 10-K annual reports from Kimball Electronics, Inc. (KE) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow KE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KE filings page.

Rhea-AI Summary

Kimball Electronics, Inc. (KE) describes itself as a global contract manufacturing and CDMO platform serving automotive, medical, and industrial customers through its Kimball Solutions offering, combining electronics manufacturing, medical disposables, drug delivery systems, and precision molded plastics. As of June 30, 2026 it operated 11 plants across the U.S., Mexico, China, India, The Netherlands, Poland, Romania, and Thailand and employed about 5,600 people worldwide. On July 1, 2026 it completed its largest acquisition to date, Helvoet Polymer Technologies B.V., expanding precision molded plastics and medical device component capabilities and adding facilities in India and The Netherlands. The company plans to change its name to Kimball Solutions, Inc., subject to share owner approval on November 13, 2026. Sales are concentrated in three end markets (automotive, medical, industrial) and three major customers accounted for about 40% of 2026 net sales, creating meaningful customer concentration risk. Kimball highlights extensive sustainability, human capital, conflict minerals, and cybersecurity programs, and details broad risk factors including supply-chain disruptions, tariffs, AI-related regulatory and operational risks, climate and ESG regulation, international operations, and covenant and liquidity risks under its credit facilities.

Rhea-AI Summary

Kimball Electronics, Inc. (KE) reported a challenging fiscal 2025 with consolidated net sales down 13% year-over-year, driven by the loss of a major automotive program, medical customer overstocking, and divestitures in industrial markets. The company completed the sale of GES for $18.5 million of proceeds and repurchased $11.9 million of common stock under an ongoing repurchase plan that authorizes up to $120 million. Liquidity improved: as of June 30, 2025 the company reported $88.8 million in cash and $284.7 million of unused borrowing capacity under credit facilities, including a $300 million revolver and a $100 million term loan added in December 2024. Capital investments totaled $33.7 million in fiscal 2025 and capital commitments were about $35 million. The company sold $19.4 million of receivables under a new receivables purchase agreement and continues restructuring actions including closure of the Tampa facility with estimated additional pre-tax charges of $0.5 to $1.0 million.